Acute Myeloid Leukemia: Why AML Strikes So Fast

Acute myeloid leukemia kills roughly 11,000 Americans a year — and most of them were healthy enough to dismiss their first symptoms as fatigue. That gap between appearance and reality is the disease’s defining cruelty, and it’s what made Tatiana Schlossberg’s decision to document her treatment publicly so unusual. Most patients don’t survive long enough to publish anything.

Tatiana Schlossberg — journalist, author, granddaughter of President John F. Kennedy — was 35 when she died on December 30, 2025. Before her death, she published a personal essay about her treatment: the chemotherapy cycles, the bone marrow biopsies, the hours suspended between hope and fear. She gave a face to a disease that quietly claims around 20,000 American lives every year.

How Acute Myeloid Leukemia Hijacks the Blood

To understand why acute myeloid leukemia moves so fast, you have to understand what it’s attacking. Bone marrow is the body’s blood-cell factory — soft, spongy tissue tucked inside the largest bones, producing red cells, platelets, and white cells around the clock. In AML, immature white blood cells called blasts undergo genetic mutations that lock them in an early developmental stage. They can’t mature. They can’t function. But they don’t stop multiplying. According to researchers at the National Cancer Institute, these blasts can flood the bone marrow within days, crowding out healthy cells and collapsing the blood system’s ability to fight infection, carry oxygen, or clot wounds.

It’s a hostile takeover at the cellular level, and it happens with terrifying efficiency. A patient might feel unusually tired on a Monday. By Thursday, a routine blood test reveals blast counts so high that hospitalization is immediate. Median time from first symptom to diagnosis is often measured in days to a few weeks — a window that feels impossibly short for patients and families alike.

That velocity is AML’s defining characteristic. It separates it from chronic leukemias, which can smolder for years before requiring treatment. AML arrives like a sudden storm, not a slow tide.

The Genetic Chaos Driving the Disease Forward

Cancer biology is rarely simple, but AML’s genetic complexity occupies a category of its own. Researchers have identified dozens of distinct mutations that can trigger the disease — in genes like FLT3, NPM1, IDH1, IDH2, and TP53, among others. Each mutation profile creates a slightly different version of the disease with different prognoses and different responses to treatment. Someone whose AML carries an NPM1 mutation without a concurrent FLT3 mutation has a meaningfully better outlook than someone with the reverse. “Acute myeloid leukemia” is less a single disease than a family of related blood cancers wearing the same name. Oncologists treating AML today must think less like generalists and more like detectives, mapping each patient’s unique genetic landscape before choosing a course of action — and that genomic complexity is part of why a single drug, a single cure, has remained so elusive for so long.

Why does this matter? Because the treatment protocol still hasn’t caught up to the diagnostic precision. Standard induction chemotherapy — typically a combination of cytarabine and an anthracycline drug, sometimes called “7+3” because of its dosing schedule — has been the frontline approach for roughly five decades. The core protocol was established in the early 1970s, and while refinements have been made, the fundamental strategy hasn’t changed as dramatically as in other cancers. Between 2017 and 2023, the FDA approved eight new drugs for AML — more than in the previous four decades combined — but even with these additions, five-year survival rates for adults over 60 remain below 15%.

Age is the cruelest variable. Younger patients tolerate intensive chemotherapy more readily. Older patients, carrying additional health burdens, often can’t. Median diagnosis age in the U.S. sits around 68 — which means the majority of patients face this disease with a physiological disadvantage already in place.

Why Treatment Feels Like Fighting on Two Fronts

Treating acute myeloid leukemia isn’t simply a matter of destroying cancer cells. Chemotherapy powerful enough to wipe out leukemic blasts also devastates the healthy bone marrow keeping the patient alive. During induction, patients enter a period called aplasia — a state of near-zero blood counts. They’re at extreme risk from infections that a healthy immune system would dismiss effortlessly. A mouth sore can become a portal for bacterial sepsis. Researchers at institutions like Johns Hopkins and MD Anderson Cancer Center have spent decades studying how to shorten this window of vulnerability, and as a major review published in Nature Reviews Cancer makes clear, the immune reconstitution phase remains one of the most dangerous periods in any leukemia patient’s journey. Tatiana Schlossberg described this terrain in her essay with a clarity that clinical papers rarely capture.

The data left no room for alternative interpretation — and any oncologist reading the survival curves already knows the transplant discussion is coming.

Bone marrow transplantation — more precisely, allogeneic hematopoietic stem cell transplantation — offers the best chance of long-term remission for many AML patients. First, the patient’s existing marrow must be destroyed using high-dose chemotherapy or radiation. Donor cells are then infused and, if everything works, engraft and begin building a new, healthy blood system. But the risks are significant: graft-versus-host disease, infection, organ damage. Not every patient qualifies. Not every patient survives it.

That reality hung over every treatment decision Tatiana’s medical team made.

Acute Myeloid Leukemia: What Targeted Therapy Promises

Turns out, the past decade has genuinely changed what’s possible for some AML patients. Targeted therapies — drugs designed to attack specific genetic vulnerabilities rather than blasting all rapidly dividing cells — have opened new pathways. Enasidenib, approved by the FDA in 2017, targets IDH2 mutations. Ivosidenib targets IDH1. Midostaurin and gilteritinib target FLT3 mutations. Venetoclax, a drug that helps cancer cells remember how to die (researchers actually call this “restoring apoptotic priming”), has transformed outcomes for older patients when combined with lower-intensity chemotherapy. A 2020 clinical trial published in the New England Journal of Medicine showed venetoclax combined with azacitidine achieved complete remission in 37% of previously untreated older patients — compared to just 17% on azacitidine alone. Those numbers represent real people, real months of life, real mornings with family.

And yet targeted therapy isn’t a cure. Resistance develops. Cancer cells mutate around the drugs blocking their survival pathways, finding new routes forward. A patient who responds beautifully to a targeted agent in their first remission may find the same drug ineffective at relapse, because the leukemia has shifted its genetic profile to escape. Patients who achieve remission — and their oncologists — are always watching for the next turn.

Researchers at institutions including the Broad Institute and the Wellcome Sanger Institute are now mapping AML’s clonal evolution in real time, tracking how the disease changes during and after treatment. The goal is to anticipate resistance before it happens, hitting the cancer at multiple vulnerabilities simultaneously to make escape harder. The data suggest this approach will eventually work. How long it takes is the open question — and for patients diagnosed today, that timeline is not academic.

Medicine has never moved this fast on AML, and it still isn’t moving fast enough.

The Human Cost and the Case for Openness

Approximately 21,000 Americans receive an AML diagnosis each year, according to the American Cancer Society’s 2024 estimates. Globally, the number exceeds 400,000 annually. These aren’t abstract statistics — they’re people in the middle of careers, families, plans. They’re 35-year-olds who had decades ahead of them.

Awareness, in cancer medicine, is not a soft outcome. When public figures like Tatiana Schlossberg speak openly about what treatment looks like from the inside — the waiting, the side effects, the moments when medicine runs out of answers — something measurable shifts in the public conversation. Research funding follows public attention. Policy follows public pressure. Consider the trajectory of breast cancer research over the past 40 years: advocacy, storytelling, and organized campaigns drove federal funding from roughly $90 million annually in the late 1980s to over $750 million by the 2020s, with survival rates rising sharply in parallel. AML hasn’t had that kind of sustained public attention, in part because it’s rarer, and in part because it often moves too fast for sustained patient advocacy.

Patients diagnosed with AML are frequently hospitalized within days and may not have the energy or the time to build public platforms. But Tatiana Schlossberg found the energy and the voice, even in the middle of the fight. In a hospital room in 2025, she wrote words that will outlast her illness. That matters beyond any single family’s grief.

How It Unfolded

• 1970s — Researchers identify the chromosomal translocation between chromosomes 8 and 21 in AML cells, the first direct link between a specific genetic abnormality and leukemia behavior; the “7+3” induction chemotherapy protocol is established around the same time and remains standard care today
• 1976 — The French-American-British classification system divides AML into eight subtypes based on cell morphology under a microscope, providing the field’s first systematic diagnostic framework
• 2017 — FDA approves enasidenib (IDH2) and midostaurin (FLT3), marking the beginning of a targeted therapy era for AML; eight approvals follow by 2023
• 2020 — New England Journal of Medicine publishes landmark venetoclax-azacitidine trial showing complete remission rates more than double those of standard care alone in older, untreated patients

By the Numbers

• Approximately 21,310 new AML cases were projected for the U.S. in 2024, with roughly 11,220 deaths (American Cancer Society, 2024)
• Median age at AML diagnosis in the United States: 68 years, with the disease significantly more common in adults over 60
• Five-year survival rate for adults under 60 with AML: approximately 40–50%; for adults over 60, below 15% in most studies
• Eight new AML-targeted therapies received FDA approval between 2017 and 2023 — more than in the previous four combined decades
• Venetoclax combination therapy achieved complete remission in 37% of older, previously untreated AML patients vs. 17% on standard care alone (New England Journal of Medicine, 2020)

Field Notes

• AML was one of the first cancers in which researchers identified a specific chromosomal abnormality — the translocation between chromosomes 8 and 21 — directly linking genetics to disease behavior. That discovery, made in the 1970s, opened the door to targeted oncology decades before the field had that name.
• Not all leukemic blasts look the same under a microscope — the French-American-British classification system, developed in 1976, originally divided AML into eight subtypes based purely on cell appearance, a system now largely replaced by genetic profiling.
• Survivors of AML who receive bone marrow transplants from donors with different blood types can, over time, convert entirely to the donor’s blood type — their own blood group effectively replaced by someone else’s.
• Researchers still can’t reliably predict which patients will develop treatment-related resistance, or explain why some AML cases with identical mutation profiles respond completely differently to the same drug combinations.

Frequently Asked Questions

Q: What makes acute myeloid leukemia so much more aggressive than other leukemias?

Acute myeloid leukemia is classified as “acute” precisely because it progresses rapidly — immature blood cells called blasts multiply without maturing, overwhelming the bone marrow within days to weeks rather than months or years. Unlike chronic leukemias, which can remain relatively stable for long periods, AML disrupts the production of all normal blood cells almost immediately. Most newly diagnosed patients require hospitalization and treatment within days of diagnosis. Without intervention, the disease is typically fatal within weeks to a few months.

Q: What does AML treatment actually involve, day to day?

Initial treatment — induction chemotherapy — typically requires a four- to six-week hospital stay. Patients receive intensive drug combinations designed to eliminate leukemic blasts while accepting the temporary destruction of their own bone marrow. During aplasia, they’re in a medically supervised state of near-zero blood counts, highly vulnerable to infection and bleeding. If remission is achieved, consolidation therapy follows: additional chemotherapy cycles or a bone marrow transplant, depending on mutation profile and overall health. Recovery is prolonged, and many patients describe the physical toll as more sustained than they anticipated.

Q: Is acute myeloid leukemia hereditary — should family members be worried?

Most AML cases are not inherited. The vast majority arise from acquired genetic mutations that develop during a person’s lifetime, often without a clear environmental cause. Some rare genetic syndromes — including Down syndrome and certain inherited bone marrow failure conditions — do increase risk. Previous cancer treatment with certain chemotherapy drugs or radiation can also raise lifetime AML risk. A family history of AML or other blood disorders warrants a conversation with a hematologist, but it doesn’t mean relatives face the same diagnosis. Routine screening for the general population isn’t currently recommended.

Tatiana Schlossberg’s story is not ultimately about celebrity or legacy or the weight of a famous surname. It’s about what happens when a person at the center of a medical crisis decides that honesty matters more than composure. Every person who reads her words and schedules a blood test, asks a harder question at their next appointment, or donates to leukemia research carries something of that decision forward. AML doesn’t wait. Neither, it turns out, should we. What would you say, if you had the chance to say something?